In this May 2024 PF Warriors special clinical trial meeting, representatives from Avalyn Pharma, including Dr. Craig Conoscenti and Dr. Allison Trucillo, introduce their new clinical research efforts focused on inhaled pirfenidone (AP01) for treating Progressive Pulmonary Fibrosis (PPF). They discuss the science behind inhaled antifibrotics, share data from completed Phase 1 studies, and outline their new global Phase 2B MIST trial. The speakers highlight improved lung exposure and reduced side effects compared to oral options. A robust Q&A session covers patient eligibility, insurance, background therapies, and broader clinical trial participation concerns from the PF community.
Dr. Allison Trucillo is Vice President of Medical Affairs at Avalyn Pharma, leading medical strategy and clinical development. With over 20 years in the pharmaceutical industry, she has worked across biotech, diagnostics, and respiratory therapeutics. She earned her MD from Baylor College of Medicine and a BS in Zoology from UT Austin.
Chapters & Timestamps
1. Overview of Avelyn Pharma and Inhaled Therapy Strategy – 6:04
2. Phase 1B ATLAS Study and Open Label Extension Results – 10:10
3. Phase 2B MIST Trial Overview – 24:05
4. Extended Audience Q&A on Clinical Trials and Access – 31:22
Disclaimer
This video is for informational purposes only and is not a substitute for professional medical advice. Always consult your doctor for medical concerns. No personal recording or redistribution without PF Warriors written permission.